Filtered By:
Cancer: Cervical Cancer
Vaccination: Cervical Cancer Vaccine

This page shows you your search results in order of date. This is page number 18.

Order by Relevance | Date

Total 929 results found since Jan 2013.

Interleukin-6 and indoleamine-2,3-dioxygenase as potential adjuvant targets for Papillomavirus-related tumors immunotherapy
In conclusion, the present study demonstrated that IL-6 and IDO negatively contribute to the activation of immune cells, particularly dendritic cells, reducing gDE7 vaccine-induced protective immune responses and, therefore, opening perspectives for the use of combined strategies based on inhibition of IL-6 and IDO as immunometabolic adjuvants for immunotherapies against HPV-related tumors.PMID:36405719 | PMC:PMC9668887 | DOI:10.3389/fimmu.2022.1005937
Source: Cancer Control - November 21, 2022 Category: Cancer & Oncology Authors: Roberta Liberato Pagni Patr ícia da Cruz Souza Rafael Pegoraro Bruna Fel ício Milazzotto Maldonado Porchia Jamile Ramos da Silva Luana Raposo de Melo Moraes Aps Mari ângela de Oliveira Silva Karine Bitencourt Rodrigues Natiely Silva Sales Lu ís Carlos Source Type: research

SOGC Guideline Retirement Notice No. 3
J Obstet Gynaecol Can. 2022 Nov;44(11):1226-1236. doi: 10.1016/j.jogc.2022.09.005.ABSTRACTThese documents have been archived because they contain outdated information. They should not be consulted for clinical use, but for historical research only. Please visit the journal website for the most recent guidelines. Prenatal Screening for Fetal Aneuploidy [J Obstet Gynaecol Can 29 (2007) 146-161] AUTHORS Anne Summers, MD, North York, ON Sylvie Langlois, MD, Vancouver, BC Phil Wyatt, MD, PhD, Toronto, ON R. Douglas Wilson, MD, Philadelphia, PA A Report on Best Practices for Returning Birth to Rural and Remote Aboriginal Communi...
Source: Rural Remote Health - November 21, 2022 Category: Rural Health Source Type: research

Impact of HPV vaccination on HPV infection and cervical related disease burden in real-world settings (HPV-RWS): protocol of a prospective cohort
This study has been retrospectively registered on clinicaltrials.gov (NCT05341284) on April 22, 2022.PMID:36401179 | DOI:10.1186/s12889-022-14474-1
Source: Cancer Control - November 19, 2022 Category: Cancer & Oncology Authors: Zhike Liu Pei Li Xueyang Zeng Xiaoying Yao Yexiang Sun Hongbo Lin Peng Shen Feng Sun Siyan Zhan Source Type: research

Cervical cancer heterogeneity: a constant battle against viruses and drugs
Biomark Res. 2022 Nov 17;10(1):85. doi: 10.1186/s40364-022-00428-7.ABSTRACTCervical cancer is the first identified human papillomavirus (HPV) associated cancer and the most promising malignancy to be eliminated. However, the ever-changing virus subtypes and acquired multiple drug resistance continue to induce failure of tumor prevention and treatment. The exploration of cervical cancer heterogeneity is the crucial way to achieve effective prevention and precise treatment. Tumor heterogeneity exists in various aspects including the immune clearance of viruses, tumorigenesis, neoplasm recurrence, metastasis and drug resistan...
Source: Cancer Control - November 18, 2022 Category: Cancer & Oncology Authors: Qian Sun Liangliang Wang Cong Zhang Zhenya Hong Zhiqiang Han Source Type: research

Cervical cancer knowledge and attitude among a cohort of female schoolteachers in Salem city - A cross-sectional survey
CONCLUSION: Primary care physicians partnering network with schoolteachers having adequate knowledge and good attitude acts as a workforce to support cervical cancer screening and human papillomavirus vaccination.PMID:36387737 | PMC:PMC9648263 | DOI:10.4103/jfmpc.jfmpc_2168_21
Source: Primary Care - November 17, 2022 Category: Primary Care Authors: S Venkata Lakshmi K Priya Deepa Lakshmi C Bharath N Saravanan Sabiha Shaheen Shaik Jithender Nagilla Source Type: research

A novel multi-epitope vaccine of HPV16 E5E6E7 oncoprotein delivered by HBc VLPs induced efficient prophylactic and therapeutic antitumor immunity in tumor mice model
In this study, the E5aa28-46, E6aa37-57 and E7aa26-57 peptides were selected and linked to form a novel multi-epitopes vaccine (E765m), which was inserted into the major immune dominant region (MIR) of hepatitis B virus core antigen (HBc) to construct a HBc-E765m chimeric virus-like particles (cVLPs). The immunogenicity and immunotherapeutic effect of the cVLPs vaccine was evaluated in immunized mice and a tumor-bearing mouse model. The results showed that HBc-E765m cVLPs elicited high E5-, E6- and E7- specific CTL and serum IgG antibody responses, and also relatively high levels of the cytokines IFN-γ, IL-4 and IL-5. Mor...
Source: Vaccine - November 14, 2022 Category: Allergy & Immunology Authors: Wang Qi Li Qingfeng Zhang Jing Zheng Maolin Zhang Zhihui Du Wangqi Zhu Shanli Chen Jun Jiang Pengfei Zhang Lifang Source Type: research

Prevention of Cervical Cancer in Low-Resource African Settings
Obstet Gynecol Clin North Am. 2022 Dec;49(4):771-781. doi: 10.1016/j.ogc.2022.08.008.ABSTRACTCervical cancer is a leading cause of cancer among women. Approximately 350,000 women die from cervical needlessly from cancer each year, and 85% of the global burden occurs in low- and middle-income countries (LMICs). Disparities in the incidence and mortality between LMICs and industrialized countries can be attributed to differences in access to human papillomavirus (HPV) vaccination and cervical cancer screening and treatment. The World Health Organization (WHO) is leading a renewed international effort to reduce the global bur...
Source: The Medical Clinics of North America - November 3, 2022 Category: General Medicine Authors: Masangu Mulongo Carla J Chibwesha Source Type: research

Comprehensive approach to costing cervical cancer prevention and control: a case study in the United Republic of Tanzania using the Cervical Cancer Prevention and Control Costing (C4P) tool
CONCLUSIONS: The C4P costing tool can assist national cervical cancer programmes to estimate monetary resources needed as well as opportunity costs of reducing national cervical cancer incidence through primary, secondary and tertiary prevention.PMID:36316680 | DOI:10.1186/s12916-022-02576-x
Source: Cancer Control - November 1, 2022 Category: Cancer & Oncology Authors: Ann Levin Safina Yuma Edwin Swai Winthrop Morgan Cindy L Gauvreau Nathalie Broutet Karene Hoi Ting Yeung Raymond Hutubessy Source Type: research

Immunogenicity and safety of two novel human papillomavirus 4- and 9-valent vaccines in Chinese women aged 20-45  years: A randomized, blinded, controlled with Gardasil (type 6/11/16/18), phase III non-inferiority clinical trial
CONCLUSIONS: This study demonstrated that the novel 4- and 9-valent HPV vaccination was highly immunogenic and generally well tolerated, both of which were non-inferior to Gardasil 4 in immunogenicity and safety.PMID:36283897 | DOI:10.1016/j.vaccine.2022.10.022
Source: Vaccine - October 25, 2022 Category: Allergy & Immunology Authors: Yajun Shu Yebin Yu Ying Ji Li Zhang Yuan Li Haiyang Qin Zhuhang Huang Zhiqiang Ou Meilian Huang Qiong Shen Zehong Li Meng Hu Chunyun Li Gaoxia Zhang Jikai Zhang Source Type: research